These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Immunoaffinity purification of polyepitope proteins against Plasmodium falciparum with chicken IgY specific to their C-terminal epitope tag. Qu JX; Lin YH; Ma RS; Wang H Protein Expr Purif; 2011 Feb; 75(2):225-9. PubMed ID: 20940054 [TBL] [Abstract][Full Text] [Related]
28. A malaria vaccine candidate based on an epitope of the Plasmodium falciparum RH5 protein. Ord RL; Caldeira JC; Rodriguez M; Noe A; Chackerian B; Peabody DS; Gutierrez G; Lobo CA Malar J; 2014 Aug; 13():326. PubMed ID: 25135070 [TBL] [Abstract][Full Text] [Related]
30. Production, quality control, stability and pharmacotoxicity of cGMP-produced Plasmodium falciparum AMA1 FVO strain ectodomain expressed in Pichia pastoris. Faber BW; Remarque EJ; Kocken CH; Cheront P; Cingolani D; Xhonneux F; Jurado M; Haumont M; Jepsen S; Leroy O; Thomas AW Vaccine; 2008 Nov; 26(48):6143-50. PubMed ID: 18804135 [TBL] [Abstract][Full Text] [Related]
31. Production of a high purity, C-tagged hepatitis B surface antigen fusion protein VLP vaccine for malaria expressed in Pichia pastoris under cGMP conditions. Mukhopadhyay E; Brod F; Angell-Manning P; Green N; Tarrant RD; Detmers FJ; Bolam EJ; Baleanu IN; Hobson M; Whale G; Morris SJ; Ashfield R; Gilbert SC; Jin J; Draper SJ; Moyle SP; Berrie EL; Hill AVS Biotechnol Bioeng; 2022 Oct; 119(10):2784-2793. PubMed ID: 35822551 [TBL] [Abstract][Full Text] [Related]
32. Studies on Immunogenicity and Antigenicity of Baculovirus-Expressed Binding Region of Plasmodium falciparum EBA-140 Merozoite Ligand. Zerka A; Rydzak J; Lass A; Szostakowska B; Nahorski W; Wroczyńska A; Myjak P; Krotkiewski H; Jaskiewicz E Arch Immunol Ther Exp (Warsz); 2016 Apr; 64(2):149-56. PubMed ID: 26439848 [TBL] [Abstract][Full Text] [Related]
33. Heat-precipitation allows the efficient purification of a functional plant-derived malaria transmission-blocking vaccine candidate fusion protein. Beiss V; Spiegel H; Boes A; Kapelski S; Scheuermayer M; Edgue G; Sack M; Fendel R; Reimann A; Schillberg S; Pradel G; Fischer R Biotechnol Bioeng; 2015 Jul; 112(7):1297-305. PubMed ID: 25615702 [TBL] [Abstract][Full Text] [Related]
34. Demonstration of the Blood-Stage Plasmodium falciparum Controlled Human Malaria Infection Model to Assess Efficacy of the P. falciparum Apical Membrane Antigen 1 Vaccine, FMP2.1/AS01. Payne RO; Milne KH; Elias SC; Edwards NJ; Douglas AD; Brown RE; Silk SE; Biswas S; Miura K; Roberts R; Rampling TW; Venkatraman N; Hodgson SH; Labbé GM; Halstead FD; Poulton ID; Nugent FL; de Graaf H; Sukhtankar P; Williams NC; Ockenhouse CF; Kathcart AK; Qabar AN; Waters NC; Soisson LA; Birkett AJ; Cooke GS; Faust SN; Woods C; Ivinson K; McCarthy JS; Diggs CL; Vekemans J; Long CA; Hill AV; Lawrie AM; Dutta S; Draper SJ J Infect Dis; 2016 Jun; 213(11):1743-51. PubMed ID: 26908756 [TBL] [Abstract][Full Text] [Related]
35. Development of a process for large scale production of PfRH5 in E. coli expression system. Raghuwanshi AS; Kumar A; Raghuwanshi N; Singh SK; Singh AK; Tripathi U; Kaviraj S; Singh S Int J Biol Macromol; 2021 Oct; 188():169-179. PubMed ID: 34364940 [TBL] [Abstract][Full Text] [Related]
36. High-level expression of the malaria blood-stage vaccine candidate Plasmodium falciparum apical membrane antigen 1 and induction of antibodies that inhibit erythrocyte invasion. Kocken CH; Withers-Martinez C; Dubbeld MA; van der Wel A; Hackett F; Valderrama A; Blackman MJ; Thomas AW Infect Immun; 2002 Aug; 70(8):4471-6. PubMed ID: 12117958 [TBL] [Abstract][Full Text] [Related]
37. Antibodies raised against receptor-binding domain of Plasmodium knowlesi Duffy binding protein inhibit erythrocyte invasion. Singh AP; Puri SK; Chitnis CE Mol Biochem Parasitol; 2002 Apr; 121(1):21-31. PubMed ID: 11985860 [TBL] [Abstract][Full Text] [Related]
38. Fusion to Tetrahymena thermophila granule lattice protein 1 confers solubility to sexual stage malaria antigens in Escherichia coli. Agrawal A; Bisharyan Y; Papoyan A; Bednenko J; Cardarelli J; Yao M; Clark T; Berkmen M; Ke N; Colussi P Protein Expr Purif; 2019 Jan; 153():7-17. PubMed ID: 30081196 [TBL] [Abstract][Full Text] [Related]
39. Production, purification and immunogenicity of a malaria transmission-blocking vaccine candidate: TBV25H expressed in yeast and purified using nickel-NTA agarose. Kaslow DC; Shiloach J Biotechnology (N Y); 1994 May; 12(5):494-9. PubMed ID: 7764708 [TBL] [Abstract][Full Text] [Related]
40. Construct design, production, and characterization of Plasmodium falciparum 48/45 R0.6C subunit protein produced in Lactococcus lactis as candidate vaccine. Singh SK; Roeffen W; Mistarz UH; Chourasia BK; Yang F; Rand KD; Sauerwein RW; Theisen M Microb Cell Fact; 2017 May; 16(1):97. PubMed ID: 28569168 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]